Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
Novo Nordisk Pharma said on March 13 that it has obtained Japanese approval for three types of single-dose subcutaneous devices for its once-weekly GLP-1 agent Ozempic (semaglutide), which has been pending listing since its approval two years ago. Ozempic was…
To read the full story
Related Article
BUSINESS
- Kyowa Kirin’s Mullick Earns 263 Million Yen in 2025; Workforce Down Sharply
March 30, 2026
- Chugai CEO Takes Home 441 Million Yen in 2025: Securities Report
March 30, 2026
- Amgen Wins Label Update for Imdelltra in Japan following PIII Data
March 30, 2026
- Eisai, Nuvation Bio’s Taletrectinib Enters EMA Review for ROS1+ NSCLC
March 30, 2026
- Eisai, MSD File Lenvima-Welireg Combo in Japan for RCC
March 30, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…